Bioresorbable vascular scaffold (BRS/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent many of the problems associated with permanent metallic stents for coronary artery bypass graft surgery. The ABSORB™ BRS (Abbott Vascular, Santa Clara, California, USA) received Conformité Européenne (CE) mark approval in 2011 and has been implanted in over 150,000 patients over the globe.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.